Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00822315 | Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis | PHASE2 | COMPLETED | 155 | — | — | Jul 1, 2009 | May 1, 2012 | Jul 17, 2013 | 9 | Brazil, France |
| NCT00002234 | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | PHASE2 | COMPLETED | 25 | — | — | - | - | Jun 24, 2005 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | efavirenz |
| 2 | EXPERIMENTAL | raltegravir 400 mg |
| 3 | EXPERIMENTAL | raltegravir 800 mg |
| Name | Type | Description |
|---|---|---|
| efavirenz | DRUG | tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg |
| raltegravir | DRUG | tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg |
| Adefovir dipivoxil | DRUG | - |
| Lamivudine | DRUG | - |
| Didanosine | DRUG | - |
Inclusion Criteria: * Adult patients (at least 18 years old) * Plasma HIV RNA \> 1000 copies/ml * HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence * ART naïve patients or * ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showin...